𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer

✍ Scribed by Dale Hardy; Chih-Chin Liu; Rui Xia; Janice N. Cormier; Wenyaw Chan; Arica White; Keith Burau; Xianglin L. Du


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
264 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND:

This study investigated whether there was a significant gap in receipt of treatment for nonsmall cell lung cancer (NSCLC) between blacks and whites, and whether the gap or disparity changed during the past 12 years from 1991 to 2002.

METHODS:

The study population consisted of 83,101 patients including 75,141 (90.4%) whites and 7960 (9.6%) blacks aged β‰₯65 years who were diagnosed with American Joint Committee on Cancer (AJCC) stages I‐IV NSCLC identified from the Surveillance, Epidemiology, and End Results (SEER) program's Medicare database. Age‐adjusted and sex‐adjusted rates and crude and adjusted odds ratios for receiving appropriate stage‐specific treatment of NSCLC were reported.

RESULTS:

For stages I‐II NSCLC combined, blacks were 37% less likely (OR, 0.63; 95% confidence interval [CI], 0.55‐0.73) to receive surgery, 42% less likely (OR, 0.58; 95% CI, 0.36‐0.92) to receive chemotherapy, and for stages III‐IV combined, 57% less likely (OR, 0.43; 95% CI, 0.30‐0.61) to receive chemotherapy compared with whites. Older patients, women, and those in lower socioeconomic quartiles had greater disparities in receipt of treatment compared with the highest income quartile. Disparity trends were not significantly narrowed during the past 12 years between blacks and whites for receipt of the above treatments.

CONCLUSIONS:

There have been substantial disparities in receiving recommended treatments between blacks and whites, and these disparities have been relatively stable without a significant trend of narrowing during the past 12 years. Efforts should focus on providing appropriate quality treatment and educating blacks on the value of having these treatments to reduce these disparities in receipt of treatment for NSCLC. Cancer 2009. Β© 2009 American Cancer Society.


πŸ“œ SIMILAR VOLUMES


Racial disparities and socioeconomic sta
✍ Xianglin L. Du; Shenying Fang; Sally W. Vernon; Hashem El-Serag; Y. Tina Shih; J πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. To the authors' knowledge, few studies have addressed racial disparities in the survival of patients with colon cancer by adequately incorporating treatment and socioeconomic factors in addition to patient and tumor characteristics. ## METHODS. The authors studied a na

Racial disparities in the use of hospice
✍ Dale Hardy; Wenyaw Chan; Chih-Chin Liu; Janice N. Cormier; Rui Xia; Eduardo Brue πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 210 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The authors investigated whether there were racial disparities in the receipt of hospice services within geographic residence and socioeconomic status (SES) levels. ## METHODS: In total, 117,894 patients aged β‰₯66 years with nonsmall cell lung cancer (NSCLC) were identi

Temporal trends and predictors of periop
✍ Jue Wang; Yong Fang Kuo; Jean Freeman; Avi B. Markowitz; James S. Goodwin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 245 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002. ## METHODS. By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 pa

The value of combined-modality therapy i
✍ Steven E. Schild; Sumithra J. Mandrekar; Aminah Jatoi; William L. McGinnis; Phil πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 140 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell l